15 Analysts Have This To Say About Blueprint Medicines
Portfolio Pulse from Benzinga Insights
15 analysts have provided mixed ratings for Blueprint Medicines (NASDAQ:BPMC) in the latest quarter. The average 12-month price target has increased to $116.47, reflecting an 18.93% rise from the previous target. Analysts have raised their price targets, with the highest being $168.00 and the lowest $75.00. Blueprint Medicines has shown strong financial performance with significant revenue growth, high net margin, and effective debt management.
July 29, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
15 analysts have provided mixed ratings for Blueprint Medicines (NASDAQ:BPMC) in the latest quarter. The average 12-month price target has increased to $116.47, reflecting an 18.93% rise from the previous target. Analysts have raised their price targets, with the highest being $168.00 and the lowest $75.00. Blueprint Medicines has shown strong financial performance with significant revenue growth, high net margin, and effective debt management.
The increase in the average 12-month price target and the strong financial performance metrics such as revenue growth, net margin, ROE, and ROA suggest a positive short-term impact on BPMC's stock price. The raised price targets by multiple analysts further support this positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100